Dextromethorphan and guaifenesin use really should be monitored carefully in clients with "very poor metabolizer" CYP2D6 enzyme stages and patients who will be sedated. This mixture medication includes a huge median poisonous dose (TD50) to median effective dose (ED50) ratio (or therapeutic index) in these patients. Delsym has an entire https://chemicalglobe.com/